Sarepta Therapeutics, Inc.
SRPT evidence brief
What we can confirm
- BioSniper Score:
- 8.6 / 10
- Market Cap:
- $2.19B
- Lead Asset:
- amondys 45 (Approved)
What it means
What to watch
Prepared research question
What matters most for SRPT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SRPT
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, gene therapy, and other genetic modalities for rare diseases, with four approved products for Duchenne muscular dystrophy and a pipeline expanding into adjacent therapeutic areas.
Key risk: ELEVIDYS non-ambulatory pause
BioSniper Score
Based on 4 of 6 signals
Market Cap
$2.19B
Cash Runway
—
Lead Asset
amondys 45 (Approved)Next Catalyst
Patent_Expiry · Jun 28, 2028Financial data as of Jun 30, 2026.
Tracking 8 pipeline candidates · 27 clinical trials · 3 catalysts · 3 FDA decisions for Sarepta Therapeutics, Inc..
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, gene therapy, and other genetic modalities for rare diseases, with four approved products for Duchenne muscular dystrophy and a pipeline expanding into adjacent therapeutic areas.
- Net product revenue for four approved products was approximately $1.9 billion in 2025 [sec · filed 2026-04-24].
- Cash & equivalents of $571.1M as of 2026-06-30 [sec].
- Convertible debt exchanges in August and December 2025 reduced total outstanding convertible notes due in 2027 from $1.15 billion to $159 million [sec · filed 2026-04-24].
- ELEVIDYS gene therapy for Duchenne muscular dystrophy was commercially launched in Japan by strategic partner Chugai Pharmaceutical, with a $40 million milestone payment upon first commercial sale [sec · filed 2026-04-24].
- CEO transition announced: Doug Ingram to retire by end of 2026 or upon appointment of replacement [sec · filed 2026-04-24].
What works
- Four approved products for Duchenne muscular dystrophy generating approximately $1.9 billion in net product revenue in 2025 [sec · filed 2026-04-24].
- Significant debt reduction achieved through convertible debt exchanges, lowering outstanding notes from $1.15 billion to $159 million [sec · filed 2026-04-24].
- Encouraging three-year results from EMBARK trial of ELEVIDYS showing durability and clinical significance [sec · filed 2026-04-24].
- Pipeline expansion into new therapeutic areas, including approval of a clinical trial application for SRP-1005 for Huntington's disease [sec · filed 2026-04-24].
What to weigh
- ELEVIDYS shipping paused for non-ambulatory patients following FDA recommendation and boxed warning for ALI and ALF [sec_mda · as of 2026-08-05].
- CEO transition introduces leadership uncertainty as Doug Ingram plans to retire by end of 2026 [sec · filed 2026-04-24].
- Net loss of $4.9M reported as of 2026-06-30 [sec].
- Future expenditures and capital requirements remain substantial and depend on multiple factors including resumption of ELEVIDYS shipments for non-ambulatory patients [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Net product revenue for four approved products was approximately $1.9 billion in 2025
“Our net product revenue for our four approved products was approximately $1.9 billion.”
SEC filings · April 24, 2026
Convertible debt exchanges reduced outstanding notes from $1.15 billion to $159 million
“Our convertible debt exchanges in August and December 2025 reduced the total amount due under our outstanding convertible notes due in 2027 from $1.15 billion to $159 million.”
SEC filings · April 24, 2026
ELEVIDYS boxed warning and removal of non-ambulatory population from indication
“In November 2025, we announced a boxed warning for ALI and ALF and removal of non-ambulatory population from the Indication and Usage section of the Prescribing Information for ELEVIDYS.”
SEC MD&A · August 5, 2026
CEO Doug Ingram to retire by end of 2026
“Mr. Ingram notified the Company of his decision to retire as Chief Executive Officer by the end of 2026 or upon the appointment of his replacement.”
SEC filings · April 24, 2026
Catalyst timeline
- 2028-06-28 · Patent_Expiry · GOLODIRSEN — Patent expiry for NDA211970; potential generic competition.
- 2030-11-12 · Patent_Expiry · CASIMERSEN — Patent expiry for NDA213026; potential generic competition.
- 2034-03-14 · Patent_Expiry · ETEPLIRSEN — Patent expiry for NDA206488; potential generic competition.
Risks & what to watch (4)›
Key risks
- ELEVIDYS non-ambulatory pause — Shipments to non-ambulatory patients paused; boxed warning added; label narrowed [sec_mda · as of 2026-08-05].
- CEO transition uncertainty — CEO Doug Ingram retiring by end of 2026; replacement not yet appointed [sec · filed 2026-04-24].
- Net loss reported — Net loss of $4.9M as of 2026-06-30 [sec].
- Substantial future capital needs — Future expenditures depend on multiple factors including resuming ELEVIDYS non-ambulatory shipments [sec_mda · as of 2026-08-05].
What to watch
- Resumption of ELEVIDYS shipments for non-ambulatory patients in the U.S. [sec_mda · as of 2026-08-05].
- CEO transition and appointment of new CEO [sec · filed 2026-04-24].
- First-in-human Phase 1 trial for SRP-1005 (Huntington's) beginning in 2026 [sec · filed 2026-04-24].
- FSHD and DM1 program readouts as highlighted in September 2026 news [news · published 2026-09-15].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Sarepta Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sarepta Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.09 · 0% dilution
Lead: Approved
8 candidates
3 upcoming, next in ~623d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 28.0%
- Days to cover
- 7.7
- Shares short
- 25,334,475
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SRPT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Sarepta Therapeutics, Inc.?
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, gene therapy, and other genetic modalities for rare diseases, with four approved products for Duchenne muscular dystrophy and a pipeline expanding into adjacent therapeutic areas.
What is Sarepta Therapeutics, Inc.'s lead drug candidate?
Sarepta Therapeutics, Inc.'s most advanced tracked candidate is amondys 45 (Approved) for Duchenne muscular dystrophy in patients with confirmed mutation of the dystrophin gene amenable to exon 45 skipping.
What is Sarepta Therapeutics, Inc.'s next catalyst?
Sarepta Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA211970" — expected June 28, 2028.
Who is the CEO of Sarepta Therapeutics, Inc.?
Dr. Michael E. Severino M.D. is the chief executive officer of Sarepta Therapeutics, Inc. (SRPT).
Where is Sarepta Therapeutics, Inc. headquartered?
Sarepta Therapeutics, Inc. (SRPT) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.